San Diego, CA, United States of America

Liqun Dong

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2012-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Liqun Dong

Introduction

Liqun Dong is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents, his work focuses on addressing critical health challenges, including cancer and allergic diseases.

Latest Patents

Among his latest patents is the invention of Anti-PD-1 antibodies and therapeutic uses thereof. This patent involves the use of antibodies to treat diseases associated with the PD-1 signaling pathway, such as cancer and various infectious diseases. Another notable patent is for methods and compositions for treating allergic diseases. This invention discloses antibodies that specifically recognize and antagonize the human TSLP receptor, providing methods to treat or ameliorate diseases mediated by TSLP signaling.

Career Highlights

Liqun Dong has worked with several reputable companies, including Novartis AG and Irm LLC. His experience in these organizations has allowed him to refine his expertise in the development of innovative therapeutic solutions.

Collaborations

Throughout his career, Liqun has collaborated with notable colleagues, including Marc Nasoff and Jieyi Wang. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Liqun Dong's innovative work in the field of biotechnology has led to significant advancements in therapeutic treatments. His patents reflect a commitment to addressing pressing health issues, showcasing his role as a key inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…